Hendrik Strebel1,2, Bernhard Haller3, Maximilian Sohn4, Wolfgang Schepp1, Felix Gundling1,5. 1. Department of Gastroenterology, Hepatology and Gastrointestinal Oncology, Bogenhausen Academic Teaching Hospital, Technical University of Munich, Munich, Germany. 2. Department for Internal Medicine I, Elblandklinikum, Meißen, Germany. 3. Institute of Medical Informatics, Statistics and Epidemiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 4. Klinik für Allgemein-, Viszeral-, Endokrine und Minimal-invasive Chirurgie, Klinikum Bogenhausen, Technische Universität München, Munich, Germany. 5. Department for Gastroenterology, Diabetics and Endocrinology, Kemperhof Hospital, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany.
Abstract
INTRODUCTION: Hepatic encephalopathy (HE), in the context of liver cirrhosis, seems to result from low-grade cerebral edema of the astrocytes. Serum brain biomarkers S-100-beta und neuron-specific enolase (NSE) are often elevated in brain injury. We hypothesized that neuromarkers S-100-beta and NSE can be used in the diagnosis of HE, compared with standardized diagnostic tools. MATERIAL AND METHODS: A prospective non-randomized intervention study was performed using L-ornithine-L-aspartate (LOLA) for HE treatment. Primary endpoint was the evaluation of neuromarkers S-100-beta and NSE for detection and diagnosis of follow-up of HE. As secondary endpoints, the efficacy of LOLA on the course of HE and the diagnostic role of Portosystemic-Encephalopathy-Syndrome score (PHES) and critical flicker frequency (CFF) were analyzed. For diagnosis of covert (CHE) and overt (OHE) HE, West-Haven criteria (WHC), PHES and CFF were assessed at study entry. LOLA was applied (20 g i.v.) for 6 days. At the end of the study, HE evaluation was repeated. S-100-beta, NSE and ammonia were assessed in each patient before, during and after therapy with LOLA. RESULTS: 30 patients were included. At study entry, CHE was diagnosed in 50% and OHE in 50% of all subjects. A total of 25 participants completed the study. After LOLA therapy, deterioration of HE occurred in <11%, while most patients showed improvement (e.g. improved CFF in 79%). No significant correlation with HE severity (as diagnosed by WHC, PHES and CFF) could be demonstrated for any biochemical parameter. In addition, there were no significant changes in brain biomarkers during the treatment period. DISCUSSION: While CFF as well as PHES showed good correlation with treatment response, S-100-beta and NSE did not significantly correlate with HE severity compared to proven diagnostic methods, and do not seem reliable biochemical markers for the follow-up under therapy.
INTRODUCTION: Hepatic encephalopathy (HE), in the context of liver cirrhosis, seems to result from low-grade cerebral edema of the astrocytes. Serum brain biomarkers S-100-beta und neuron-specific enolase (NSE) are often elevated in brain injury. We hypothesized that neuromarkers S-100-beta and NSE can be used in the diagnosis of HE, compared with standardized diagnostic tools. MATERIAL AND METHODS: A prospective non-randomized intervention study was performed using L-ornithine-L-aspartate (LOLA) for HE treatment. Primary endpoint was the evaluation of neuromarkers S-100-beta and NSE for detection and diagnosis of follow-up of HE. As secondary endpoints, the efficacy of LOLA on the course of HE and the diagnostic role of Portosystemic-Encephalopathy-Syndrome score (PHES) and critical flicker frequency (CFF) were analyzed. For diagnosis of covert (CHE) and overt (OHE) HE, West-Haven criteria (WHC), PHES and CFF were assessed at study entry. LOLA was applied (20 g i.v.) for 6 days. At the end of the study, HE evaluation was repeated. S-100-beta, NSE and ammonia were assessed in each patient before, during and after therapy with LOLA. RESULTS: 30 patients were included. At study entry, CHE was diagnosed in 50% and OHE in 50% of all subjects. A total of 25 participants completed the study. After LOLA therapy, deterioration of HE occurred in <11%, while most patients showed improvement (e.g. improved CFF in 79%). No significant correlation with HE severity (as diagnosed by WHC, PHES and CFF) could be demonstrated for any biochemical parameter. In addition, there were no significant changes in brain biomarkers during the treatment period. DISCUSSION: While CFF as well as PHES showed good correlation with treatment response, S-100-beta and NSE did not significantly correlate with HE severity compared to proven diagnostic methods, and do not seem reliable biochemical markers for the follow-up under therapy.
Authors: Nathan M Bass; Kevin D Mullen; Arun Sanyal; Fred Poordad; Guy Neff; Carroll B Leevy; Samuel Sigal; Muhammad Y Sheikh; Kimberly Beavers; Todd Frederick; Lewis Teperman; Donald Hillebrand; Shirley Huang; Kunal Merchant; Audrey Shaw; Enoch Bortey; William P Forbes Journal: N Engl J Med Date: 2010-03-25 Impact factor: 91.245
Authors: Alexander L Gerbes; Joachim Labenz; Beate Appenrodt; Matthias Dollinger; Felix Gundling; Veit Gülberg; Axel Holstege; Petra Lynen-Jansen; Christian J Steib; Jonel Trebicka; Reiner Wiest; Alexander Zipprich Journal: Z Gastroenterol Date: 2019-05-24 Impact factor: 2.000
Authors: Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong Journal: Hepatology Date: 2014-07-08 Impact factor: 17.425
Authors: Christian Labenz; Marcus-Alexander Wörns; Jörn M Schattenberg; Yvonne Huber; Peter Robert Galle; Joachim Labenz Journal: Z Gastroenterol Date: 2017-07-12 Impact factor: 2.000
Authors: Felix Gundling; Edin Zelihic; Holger Seidl; Bernhard Haller; Andreas Umgelter; Wolfgang Schepp; Christoph Dodt Journal: Ann Hepatol Date: 2013 Jan-Feb Impact factor: 2.400
Authors: Jasmohan S Bajaj; James B Wade; Douglas P Gibson; Douglas M Heuman; Leroy R Thacker; Richard K Sterling; R Todd Stravitz; Velimir Luketic; Michael Fuchs; Melanie B White; Debulon E Bell; HoChong Gilles; Katherine Morton; Nicole Noble; Puneet Puri; Arun J Sanyal Journal: Am J Gastroenterol Date: 2011-05-10 Impact factor: 10.864